SCHEMBL6833853

SCHEMBL6833853

CC(O)NC(=S)Nc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.62
LMNA P02545 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
HPGD P15428 2/20 0.62
ALDH1A1 P00352 3/20 0.61
TAS2R38 P59533 2/20 0.61
CYP3A4 P08684 1/20 0.61
HSD17B10 Q99714 1/20 0.61
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
NOX1 Q9Y5S8 1/20 0.57
ALOX12 P18054 1/20 0.56
HTT P42858 1/20 0.56
EPHX2 P34913 1/20 0.54
CNR1 P21554 2/20 0.53
MAOA P21397 1/20 0.52
MAOB P27338 1/20 0.52
CYP1A2 P05177 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456616 0.86 ALDH1A1 (0.72) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL13754414 0.82 GAA (0.65) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL5455317 0.81 HSD17B10 (0.64) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL3070340 0.80 ALDH1A1 (0.61) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL24064909 0.79 GAA (0.71) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL11283059 0.79 STAT3 (0.61) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL22957976 0.79 GAA (0.71) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL7748286 0.79 GAA (0.61) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL7748287 0.79 GAA (0.61) GAALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL11326942 0.79 GAA (0.53) GAALMNASMN1; SMN2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082774-A1 Novel phosphate and thiophosphate protecting groups ISIS PHARMACEUTICALS, INC. 2004-04-29 US disclosed
US-6610837-B1 Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization ISIS PHARMACEUTICALS, INC. 2003-08-26 US disclosed
US-6121437-A SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS ISIS PHARMACEUTICALS, INC. (US) 2000-09-19 US disclosed
US-4101780-A TREATING SILVER WITH A RADIOACTIVE SULFUR COMPOUND SUCH AS THIOUREA OR DERIVATIVES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) 1978-07-18 US disclosed
US-3932182-A An organic photoconductive composition comprising an organic photoconductive compound and a sensitizing compound having an active methylene group MITSUBISHI PAPER MILLS, LTD. (JA) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082774-A1 Novel phosphate and thiophosphate protecting groups TYMP, MTAP, PPIP5K2 GAA 1448/4885LMNA 1231/4885SMN1; SMN2 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.